IP Library › Granted Patent US 12,509,655
Granted Patent B2
US 12,509,655 · App. 17/599,050 · Granted Dec 30, 2025

Integrated and continuous recombinant protein manufacturing

Inventors: Jonathan Coffman (Gaithersbury, MD); Scott A. Godfrey (Pleasanton, CA); Raquel Orozco (Richmond, CA); Robert Lee Fahrner (Ellisville, MO); Marcus Andre Fiadeiro (Cambridge, MA); Robert E. Kottmeier (St. Louis, MO); Joseph K. Mclaughlin (Ballwin, MO); Jeffrey Richard Salm (Wakefield, MA)
Assignee: Boehringer Ingelheim International GmbH
C12M23/28C12M33/14C12M47/10C12M47/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,509,655
App. No.
17/599,050
Granted
Dec 30, 2025
Kind
B2
Abstract

Integrated systems and methods for the manufacturing of recombinant proteins in mammalian cells are provided. The systems and methods include a single-use bioreactor (SUB), a tangential flow filtration system, a column chromatography skid, a tankless hold, a virus inactivation plug flow reactor, and pumps.

Claims (18)

1 . An automated integrated single-use continuous cell culture system comprising, in the following order:

a. a single-use perfusion bioreactor (SUB) between 10 L and 2250 L,

b. a single-use tangential flow filtration system generating a permeate,

c. a single-use dual-column capture column chromatography skid configured to operate in parallel generating an effluent, wherein the capture column is Protein A;

d. a tankless hold comprising an elution stream chamber consisting of a tubing and having a volume of 1.1 to 3 times the volume of a single capture column;

e. a single-use virus inactivation plug flow reactor, wherein the single-use virus inactivation plug flow reactor is a continuous viral inactivation reactor including an inlet, an outlet, and a tubular flow path having a set of alternating turns that form a serpentine pattern between the inlet and the outlet, wherein the tubular flow path includes a diameter of from 0.6 cm to 0.7 cm, and wherein the set of alternating turns are segmented vertically into at least two stacked layers, wherein each of the at least two stacked layers include a thickness of from 0.7 cm to 1.2 cm;

f. an individual anion-exchange chromatography column;

g. a single pass tangential flow filtration system;

h. a single use mixer; and

i. a first set of pumps operating with a range of about 60 mL/min to about 5 L/min, or about 60 ml/min to about 600 mL/min and a second set of pumps operating with a range of about 125 mL/min to about 2.5 L/min;

wherein the single-use SUB is fluidically attached, without a tank and by tubing, to the single-use tangential flow filtration system;

wherein the permeate is transferred, without a tank, by ¼ inch to ⅜ inch single-use tubing to the single-use dual-column capture column chromatography skid;

wherein the effluent is transferred, without a tank, by single-use ¼ inch to ⅜ inch tubing to the tankless hold;

wherein the tankless hold is fluidically connected to the single-use virus inactivation plug flow reactor;

wherein the virus inactivation plug flow reactor is fluidically connected without a tank and by tubing to the anion exchange chromatography column,

wherein the anion exchange chromatography column is fluidically connected without a tank and by tubing to the single pass tangential flow filtration system, and

wherein the single pass tangential flow filtration system is fluidically connected without a tank and by tubing to the single use mixer, and wherein the first and second sets of pumps are fluidically connected to one or more of components a-i.

2 . The automated integrated single-use continuous cell culture system of claim 1 , wherein the system is capable of processing between 10 g and 5,000 g of recombinant protein per day.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2023
From: FAHRNER, ROBERT LEE; FIADEIRO, MARCUS ANDRE; KOTTMEIER, ROBERT EDWARD; MCLAUGHLIN, JOSEPH KEITH; SALM, JEFFREY RICHARD
To: PFIZER INC.
Reel/Frame 065353/0316 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2023
From: PFIZER INC.
To: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Reel/Frame 065353/0381 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2023
From: BOEHRINGER INGELHEIM FREMONT, INC.
To: BOEHRINGER INGELHEIM BIOPHARMACEUTICALS GMBH
Reel/Frame 065308/0088 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2023
From: BOEHRINGER INGELHEIM BIOPHARMACEUTICALS GMBH
To: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Reel/Frame 065308/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2023
From: OROZCO, RAQUEL; GODFREY, SCOTT A.; COFFMAN, JONATHAN
To: BOEHRINGER INGELHEIM FREMONT, INC.
Reel/Frame 063042/0172 →
Continuity (3)
Provisional Application 62899829 · Sep 13, 2019
Provisional Application 62827504 · Apr 1, 2019
Related Publication 20220162535A1 · May 26, 2022
References Cited (15)
US 11104875B2 · Hiller et al. · 2021 [cited by applicant]
US 20140255994A1 · Konstantinov et al. · 2014 [cited by applicant]
US 20150064769A1 · Xenopoulos · 2015 [cited by examiner]
US 20150158907A1 · Zhou et al. · 2015 [cited by applicant]
US 20170320909A1 · Xenopoulos et al. · 2017 [cited by applicant]
US 20190275519A1 · Castillo et al. · 2019 [cited by applicant]
EP 2682168A1 · 2014 [cited by applicant]
JP 2011215008A · 2011 [cited by applicant]
WO 2001060974A2 · 2001 [cited by applicant]
WO 2006056469A1 · 2006 [cited by applicant]
WO 2013116421A1 · 2013 [cited by applicant]
WO 2014004281A1 · 2014 [cited by applicant]
WO 2015039115A1 · 2015 [cited by applicant]
WO WO2018035116A1 · 2018 [cited by examiner]
International Search Report and Written Opinion for corresponding application, PCT/US2020/025334, date of mailing Jul. 2, 2020. [cited by applicant]